LQDA Liquidia Technologies Inc.

7.15
+0.15  (+2%)
Previous Close 7
Open 7.09
Price To Book 6.81
Market Cap 184,623,396
Shares 25,821,454
Volume 210,575
Short Ratio
Av. Daily Volume 180,932
Stock charts supplied by TradingView

NewsSee all news

  1. Liquidia Technologies Announces $22.4 Million Private Placement

    RESEARCH TRIANGLE PARK, N.C., Dec. 24, 2019 (GLOBE NEWSWIRE) -- Liquidia Technologies, Inc. (NASDAQ:LQDA) ("Liquidia"), a late-stage clinical biopharmaceutical company focused on the development and commercialization

  2. Liquidia Technologies Reports Third Quarter 2019 Financial Results and Provides Corporate Update

    Completed Registrational Studies of LIQ861 to Include in New Drug Application (NDA)Targeting Submission of NDA for LIQ861 in 1Q 2020Management to Host Webcast and Conference Call Today at 8:00 a.m. ET RESEARCH TRIANGLE

  3. Liquidia to Report Third Quarter 2019 Financial Results and Provide Corporate Update on November 13, 2019

    RESEARCH TRIANGLE PARK, N.C., Nov. 06, 2019 (GLOBE NEWSWIRE) -- Liquidia Technologies, Inc. (NASDAQ:LQDA) ("Liquidia" or the "Company"), a late-stage clinical biopharmaceutical company, today announced that third

  4. Liquidia Technologies Appoints Industry Veteran Katie Rielly-Gauvin to Board of Directors

    RESEARCH TRIANGLE PARK, N.C., Nov. 01, 2019 (GLOBE NEWSWIRE) -- Liquidia Technologies, Inc. (NASDAQ:LQDA) ("Liquidia" or the "Company"), a late-stage clinical biopharmaceutical company, today announced the appointment

  5. Liquidia to Present at Cantor 2019 Global Healthcare Conference

    RESEARCH TRIANGLE PARK, N.C., Sept. 25, 2019 (GLOBE NEWSWIRE) -- Liquidia Technologies, Inc. (NASDAQ:LQDA) ("Liquidia" or the "Company"), a late-stage clinical biopharmaceutical company, announced that Neal Fowler,

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 2 trials planned for 2020.
LIQ865
Post-operative pain
NDA filing due 1Q 2020.
LIQ861 - INSPIRE
Pulmonary arterial hypertension

Latest News

  1. Liquidia Technologies Announces $22.4 Million Private Placement

    RESEARCH TRIANGLE PARK, N.C., Dec. 24, 2019 (GLOBE NEWSWIRE) -- Liquidia Technologies, Inc. (NASDAQ:LQDA) ("Liquidia"), a late-stage clinical biopharmaceutical company focused on the development and commercialization

  2. Liquidia Technologies Reports Third Quarter 2019 Financial Results and Provides Corporate Update

    Completed Registrational Studies of LIQ861 to Include in New Drug Application (NDA)Targeting Submission of NDA for LIQ861 in 1Q 2020Management to Host Webcast and Conference Call Today at 8:00 a.m. ET RESEARCH TRIANGLE

  3. Liquidia to Report Third Quarter 2019 Financial Results and Provide Corporate Update on November 13, 2019

    RESEARCH TRIANGLE PARK, N.C., Nov. 06, 2019 (GLOBE NEWSWIRE) -- Liquidia Technologies, Inc. (NASDAQ:LQDA) ("Liquidia" or the "Company"), a late-stage clinical biopharmaceutical company, today announced that third

  4. Liquidia Technologies Appoints Industry Veteran Katie Rielly-Gauvin to Board of Directors

    RESEARCH TRIANGLE PARK, N.C., Nov. 01, 2019 (GLOBE NEWSWIRE) -- Liquidia Technologies, Inc. (NASDAQ:LQDA) ("Liquidia" or the "Company"), a late-stage clinical biopharmaceutical company, today announced the appointment

  5. Liquidia to Present at Cantor 2019 Global Healthcare Conference

    RESEARCH TRIANGLE PARK, N.C., Sept. 25, 2019 (GLOBE NEWSWIRE) -- Liquidia Technologies, Inc. (NASDAQ:LQDA) ("Liquidia" or the "Company"), a late-stage clinical biopharmaceutical company, announced that Neal Fowler,

  6. Liquidia Technologies Appoints Industry Veteran Dr. Joanna Horobin to Board of Directors

    RESEARCH TRIANGLE PARK, N.C., Sept. 12, 2019 (GLOBE NEWSWIRE) -- Liquidia Technologies, Inc. (NASDAQ:LQDA) ("Liquidia" or the "Company"), a late-stage clinical biopharmaceutical company, today announced the appointment

  7. Liquidia to Present at H.C. Wainwright Healthcare Conference

    RESEARCH TRIANGLE PARK, N.C., Sept. 03, 2019 (GLOBE NEWSWIRE) -- Liquidia Technologies, Inc. (NASDAQ:LQDA) ("Liquidia" or the "Company"), a late-stage clinical biopharmaceutical company, announced that Neal Fowler,